Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the efficacy of Asacol™ 4.8 g/day (800 mg
tablets) to induce clinical and endoscopic remission after 6 weeks of treatment compared to
placebo in subjects with active ulcerative colitis (UC).